Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) – Cantor Fitzgerald cut their FY2018 earnings per share (EPS) estimates for shares of Aerie Pharmaceuticals in a research note issued to investors on Monday. Cantor Fitzgerald analyst E. Piros now forecasts that the company will post earnings per share of ($2.97) for the year, down from their previous estimate of ($2.17). Cantor Fitzgerald currently has a “Buy” rating and a $69.00 target price on the stock.

AERI has been the subject of several other reports. Mizuho restated a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a report on Wednesday, October 25th. Zacks Investment Research upgraded shares of Aerie Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Tuesday, October 24th. Needham & Company LLC restated a “buy” rating and issued a $65.00 price objective on shares of Aerie Pharmaceuticals in a report on Sunday, September 17th. Stifel Nicolaus restated a “buy” rating and issued a $70.00 price objective on shares of Aerie Pharmaceuticals in a report on Friday, July 28th. Finally, Canaccord Genuity set a $65.00 target price on shares of Aerie Pharmaceuticals and gave the company a “buy” rating in a research note on Wednesday, October 11th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and twelve have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $71.43.

COPYRIGHT VIOLATION NOTICE: This article was first posted by American Banking News and is the sole property of of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international trademark & copyright legislation. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/11/22/fy2018-earnings-estimate-for-aerie-pharmaceuticals-inc-aeri-issued-by-cantor-fitzgerald.html.

Shares of Aerie Pharmaceuticals (NASDAQ:AERI) traded down $0.15 on Wednesday, reaching $61.25. 91,620 shares of the company’s stock traded hands, compared to its average volume of 522,089. The company has a quick ratio of 15.24, a current ratio of 15.24 and a debt-to-equity ratio of 0.78. Aerie Pharmaceuticals has a twelve month low of $35.20 and a twelve month high of $66.25.

Several institutional investors and hedge funds have recently made changes to their positions in the stock. GSA Capital Partners LLP increased its position in shares of Aerie Pharmaceuticals by 31.3% during the third quarter. GSA Capital Partners LLP now owns 6,444 shares of the company’s stock valued at $313,000 after acquiring an additional 1,538 shares in the last quarter. Iguana Healthcare Management LLC increased its position in shares of Aerie Pharmaceuticals by 5.3% during the third quarter. Iguana Healthcare Management LLC now owns 100,000 shares of the company’s stock valued at $4,860,000 after acquiring an additional 5,000 shares in the last quarter. Neuberger Berman Group LLC increased its position in shares of Aerie Pharmaceuticals by 100.0% during the third quarter. Neuberger Berman Group LLC now owns 25,000 shares of the company’s stock valued at $1,215,000 after acquiring an additional 12,500 shares in the last quarter. California Public Employees Retirement System increased its position in shares of Aerie Pharmaceuticals by 47.5% during the third quarter. California Public Employees Retirement System now owns 7,525 shares of the company’s stock valued at $366,000 after acquiring an additional 2,425 shares in the last quarter. Finally, Ladenburg Thalmann Financial Services Inc. bought a new stake in shares of Aerie Pharmaceuticals during the third quarter valued at approximately $204,000.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development and commercialization of therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company’s product candidates include Rhopressa (netarsudil ophthalmic solution) 0.02% (Rhopressa), and Roclatan (netarsudil/latanoprost ophthalmic solution) 0.02%/0.005% (Roclatan).

Receive News & Ratings for Aerie Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.